https://doi.org/10.1200/jco.1998.16.4.1310 · Full text
Journal: Journal of Clinical Oncology, 1998, №4, p.1310-1317
Publisher: American Society of Clinical Oncology (ASCO)
Authors:
- M Al-Sarraf
- M LeBlanc
- P G Giri
- K K Fu
- J Cooper
- T Vuong
- A A Forastiere
- G Adams
- W A Sakr
- D E Schuller
- J F Ensley
Abstract
<jats:sec>PURPOSE The Southwest Oncology Group (SWOG) coordinated an Intergroup study with the participation of Radiation Therapy Oncology Group (RTOG), and Eastern Cooperative Oncology Group (ECOG). This randomized phase III trial compared chemoradiotherapy versus radiotherapy alone in patients with nasopharyngeal cancers. </jats:sec><jats:sec>MATERIALS AND METHODS Radiotherapy was administered in both arms: 1.8- to 2.0-Gy/d fractions Monday to Friday for 35 to 39 fractions for a total dose of 70 Gy. The investigational arm received chemotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43 during radiotherapy; postradiotherapy, chemotherapy with cisplatin 80 mg/m2 on day 1 and fluorouracil 1,000 mg/m2/d on days 1 to 4 was administered every 4 weeks for three courses. Patients were stratified by tumor stage, nodal stage, performance status, and histology. </jats:sec><jats:sec>RESULTS Of 193 patients registered, 147 (69 radiotherapy and 78 chemoradiotherapy) were eligible for primary analysis for survival and toxicity. The median progression-free survival (PFS) time was 15 months for eligible patients on the radiotherapy arm and was not reached for the chemo-radiotherapy group. The 3-year PFS rate was 24% versus 69%, respectively (P < .001). The median survival time was 34 months for the radiotherapy group and not reached for the chemo-radiotherapy group, and the 3-year survival rate was 47% versus 78%, respectively (P = .005). One hundred eighty-five patients were included in a secondary analysis for survival. The 3-year survival rate for patients randomized to radiotherapy was 46%, and for the chemoradiotherapy group was 76% (P < .001). </jats:sec><jats:sec>CONCLUSION We conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival. </jats:sec>
Publications that cite this publication
Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck
Mohan Suntharalingam, Michael L. Haas, David A. Van Echo, Robert Haddad, Maria C. Jacobs, Sharon Levy, William C. Gray, Robert A. Ord, Barbara A. Conley
https://doi.org/10.1002/1097-0142(20010201)91:3<548::aid-cncr1033>3.0.co;2-a ·
2001, Cancer, №3, p.548-554
Scopus
WoS
Crossref citations:31
The role of chemotherapy in the primary management of nasopharyngeal cancer
D.J. Adelstein
https://doi.org/10.1046/j.1365-2273.2000.00329-7.x
2000, Clinical Otolaryngology, №1, p.77-78
Scopus
Crossref citations:0
Nasopharyngeal carcinoma in children under 15 years of age: A retrospective review of 65 patients
S. Sahraoui, A. Acharki, A. Benider, N. Bouras, A. Kahlain
https://doi.org/10.1023/a:1008325925164 · Full text
1999, Annals of Oncology, №12, p.1499-1502
Scopus
WoS
Crossref citations:31
Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma
Cheng Lin, Keyu Lin, Bin Zhang, Ying Su, Qiaojuan Guo, Tianzhu Lu, Yuanji Xu, Shaojun Lin, Jingfeng Zong, Jianji Pan
https://doi.org/10.1093/oncolo/oyac024 ·
2022, The Oncologist, №4, p.e340-e349
Scopus
WoS
Crossref citations:8
Determination of tumor kinetics: strategies for the delivery of radiotherapy and chemotherapy
Mark A. Ritter
https://doi.org/10.1097/00001622-199905000-00007
1999, Current Opinion in Oncology, №3, p.177
Scopus
WoS
Crossref citations:7
Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer
Richard H. Wheeler, Sharon Spencer, Donald Buchsbaum, Francisco Robert
https://doi.org/10.1097/00001622-199905000-00009
1999, Current Opinion in Oncology, №3, p.187
Scopus
WoS
Crossref citations:14
Surgical options for continuing treatment of recurrent nasopharyngeal carcinoma
William Ignace Wei, Anthony Po Wing Yuen, Wai Kuen Ho
https://doi.org/10.1097/00020840-200004000-00009
2000, Current Opinion in Otolaryngology & Head and Neck Surgery, №2, p.117-121
Scopus
WoS
Crossref citations:3
Hyperfractionated Radiotherapy Followed by Adjuvant Chemotherapy for Nasopharyngeal Cancer: Report of Seven Cases
T. Toita, K. Ogawa, M. Kamata, S. Kojya, T. Itokazu, Y. Kakinohana, S. Iraha, M. Yoshinaga, Y. Zukeran, S. Sawada
https://doi.org/10.1093/jjco/29.3.160 · Full text
1999, Japanese Journal of Clinical Oncology, №3, p.160-163
Scopus
WoS
Crossref citations:1
Long-Term Follow-up on an Intensified Treatment Regimen for Advanced Resectable Head and Neck Squamous Cell Carcinomas
John C. Grecula, David E. Schuller, Roy Smith, Chris A. Rhoades, Subir Nag, Constance J. Bauer, Amit Agrawal, Jessie L.-S. Au, Donn Young, Reinhard A. Gahbauer
https://doi.org/10.1081/cnv-100000147 ·
2001, Cancer Investigation, №2, p.127-136
Scopus
WoS
Crossref citations:3
A New Intensified Therapeutic Regimen for Advanced Head and Neck Squamous Cell Carcinomas: Where Does It Fit Among Available Treatment Options?
David G. Pfister, Eric J. Sherman, Suzanne L. Wolden
https://doi.org/10.1081/cnv-100000157 ·
2001, Cancer Investigation, №2, p.217-218
Scopus
WoS
Crossref citations:0
Find all citations of the publication